IN DEVELOPMENT FOR MORE ON THIS
WE'RE JOINED BY JEFFREY STEIN
PRESIDENT AND CHIEF EXECUTIVE
OFFICER AND SIDDHARTHA
THERAPEUTICS GREAT TO HAVE YOU
ON
THIS MORNING IN SIMPLE TERMS
CAN YOU BREAK DOWN FOR US HOW
ABC'S WORK AT PREVENTING
ILLNESS.
>> ABC'S OR BY IMMUNOTHERAPIES
AND BY THAT MEANS OR
2 PIECES AND YOU CAN THINK OF
IT AS AN ARROW WHERE THE HAIR
ARROWHEAD IT'S A VERY POTENT
ANTIVIRAL MOLECULE AND IT'S
ATTACHED TO A FRAGMENT OF A
HUMAN ANTIBODY
AND THAT YOU'RE GOING TO VISION
COULD BE THE FEATHERS THAT
PROVIDE STABILITY IN THE CASE
OF THESE ANTIVIRAL CONTRA CUTS
OR ABC'S
THAT'S LONG TERMS STABILITY IN
THE BODY SUCH THAT OUR FLU
MOLECULES IN OUR LEAD MOLECULE
CDS THE 88 WHICH IS THE BASIS
OF THE COLLABORATION WITH
JOHNSON PHARMACEUTICALS WE
ESTIMATE COULD BE ADMINISTERED
AT A SINGLE SMALL DOSHI THERE
SEPTA TENNIS LEE OR
STILL EARLY. ONE SUPER FLU
SEASON IN PROVIDE UNIVERSAL
PROTECTION AND TREATMENT
AGAINST ALL SEASONAL AS WELL AS
PANDEMIC STRANGE.
>> SO JOHNSON AND
JOHNSON CLEARLY SEEING TONS OF
POTENTIAL HERE WHAT EXACTLY
DOES IT MEAN THAT THEY'RE GOING
TO
HAVE THE EXCLUSIVE WORLDWIDE
RIGHTS TO THESE ABC'S.
>> WHAT THAT MEANS THAT THEY
WILL HAVE THE RIGHT TO
COMMERCIALIZE THE ABC'S
ONCE APPROVED. WE ARE LEADING
THE DEVELOPMENT THROUGH THE
FIRST PHASE
2 STUDY AT THAT POINT IN TIME
JNJ HAS A PERIOD OF TIME
TO THEN. ACQUIRE THE PROGRAM
AND PUT IT INTO LATE-STAGE
DEVELOPMENT COMMERCIALIZATION.
>> OKAY SO IN THEORY, I'M JUST
TRYING. I'M NOT THAT I EVEN
WANT.
>> IMAGINE ANOTHER PANDEMIC AT
THIS POINT BECAUSE WE'RE STILL.
>> VERY IN THE MIDDLE OF THE
COVID PANDEMIC BUT IN THEORY
JUST A FEW YEARS
FROM NOW.
>> NOW ANOTHER TYPE OF
RESPIRATORY VIRUS EMERGES THAT
THAT'S
COMPLETELY NEW HOW MIGHT
THESE ABC'S HELP AND WHAT WOULD
BE THE PRACTICAL IMPLICATION
WOULD YOU GET KIND
OF LIKE AND ABC SHOT IT IF THE
IF IT WAS EMERGING HOW DOES IT
WORK.
>> COVID-19 YEAR IT
BELIEVED VERY BROADLY THAT THE
NEXT PANDEMIC WOULD BE
INFLUENZA IN 2017 THERE'S SOME
80 MILLION DEATHS IN THE
U.S. DUE TO INFLUENZA AND SO WE
AND OTHERS HAVE BEEN GEARING UP
FOR AN
INFLUENZA PANDEMIC CERTAINLY
THAT'S STILL A HOWEVER, THE
PROOF
OF CONCEPT THAT WE HAVE
DEVELOPED IN THE LEARNINGS WE
HAVE ACQUIRED FROM THE
DEVELOPMENT OF OUR
INFLUENZA. ABC'S WE ARE
APPLYING TO OTHER RESPIRATORY
VIRUSES AS WELL STAR KOBE TO
RESPIRATORY SYNCYTIAL VIRUS AND
OTHERS.
>> IN TERMS OF THE FLU SHOT SO
WE ALREADY HAVE A
FLU VACC MAXINE HOW IS THIS
DIFFERENT WITH THIS REPLACE THE
FLU VACCINE OR WOULD YOU GET IT
IN ADDITION TO A FLU VACCINE.
>> WELL VACCINES ARE STILL OUR
BEST DEFENSE AGAINST ALL VIRAL
INFECTIONS. SO I WANTED BE VERY
CLEAR
ABOUT THAT HOWEVER WITH RESPECT
TO THE
FLU VACCINES. THE OVERALL
EFFECTIVENESS THE VACCINE
EFFECTIVENESS WHICH IS WE HAVE
GOT SOMETHING WE'RE HEARING UP
A LOT NOWADAYS IS RATHER LOW
ON AVERAGE THE VACCINE
EFFECTIVENESS IS ABOUT
49 PERCENT RIGHT WHICH DOES NOT
ENGENDER A LOT OF CONFIDENCE
AND IN FACT CONTRIBUTES TO
VACCINE HESITANCY SO
WITH OUR ABC'S FROM THE DATA WE
HAVE TO DATE IT SUGGESTS THAT
THEY ARE EFFECTIVE AGAINST ALL
STRAINS ALL PANDEMIC AS WELL AS
SEASONAL STRAINS AND THAT'S WHY
WE'RE EXCITED TO GET THIS IN
COOK INTO THE CLINIC AND WHY WE
ARE EXCITED TO COLLABORATE WITH
YOU ON SOME PHARMACEUTICALS.
>> SO YOU AGAIN RECEIVED
THIS UPFRONT PAYMENT FROM
JOHNSON JOHNSON FOR
780 MILLION DOLLARS FROM WHERE
ELSE COULD INVESTORS
ADDITIONAL REVENUE IF THESE
ABC'S REALLY DO PROVED TO BE
EFFECTIVE.
>> JUST TO CLARIFY THE OVERALL
VALUE OF THE DEAL IS
780 MILLION DOLLARS. SO THAT'S
POTENTIAL PAYMENTS GOING
FORWARD
UP FRONT. WE RECEIVED
27 MILLION TO START
THE COLLAPSE RATION. THERE'S AN
ESTIMATED 58 MILLION DOLLARS IN
R AND
D SPENDING WE COULD THEN
AS WE DEVELOP THE DRUG AND THEN
ANOTHER 695 MILLION DOLLARS
GOING FORWARD. SO YOU KNOW IT
IS A VERY IMPORTANT DEAL NOT
ONLY TO US BUT AS WELL AS TO
JOHNSON. AND I THINK IT IS
COMMENSURATE WITH THE POTENTIAL
OF OUR ABC'S.
>> AND AGAIN IN TERMS
OF THE THEIR MONETARY POTENTIAL
DOWN THE WHERE WHERE DOES THAT
COME FROM.
>> WELL CONSIDER EVEN IF THERE
WERE SUCH A THING AS A
UNIVERSAL FLU VACCINE. VACCINES
ONLY WORK BY THE IMMUNE
RESPONSE IN
THE INDIVIDUAL. IN THE U.S.
ALONE THERE'S UPWARDS OF A
100 MILLION PEOPLE THAT ARE IN
THIS VULNERABLE POPULATION THAT
DO NOT RESPOND WELL TO VACCINES
SO EVEN IF THERE A PERFECT
UNIVERSAL VACCINE. YOU HAVE A
VERY LARGE PROPORTION OF THE
POPULACE WOULD NOT RESPOND
ADEQUATELY AND THAT'S WHY A
LONG
ACTING DRUG SUCH AS AND COULD
BE BENEFICIAL IN THAT VERY
LARGE POPULATION.
>> ON THAT NOTE HOW LONG DOES
AN ABC POTENTIALLY LAST.
>> SO OUR LEAD MOLECULE CD 3.88
UP BASED ON ALL THE DATA WE
HAVE TODAY
SUGGESTS THAT A SINGLE SMALL SO
CUTANEOUS OR INTO MUSCULAR DOSE
COULD LAST FOR 4 TO 6 MONTHS
OR BASICALLY THE LENGTH OF THE
ENTIRE FLU SEASON.